A new report compiled by Deloitte and featured on the Fierce Biotech web site, highlights the continuing woes of the biopharma sector. The report states that the cost of bringing new drugs to market has risen by 18% since 2010, with an accompanying decline in forecast sales of 43% over the same period. In effect then, this amounts to a decline in the sector's return on investment (ROI) of approaximately 50%. This is bad news indeed for a sector already suffering from more than a decade of declining ROI - a situation we have discussed at some length here on The Digital Biologist.
© The Digital Biologist | All Rights Reserved